

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants	:	Miller et al.	)	Examiner:
			)	To Be Assigned
Serial No.	:	Division of 10/106,521	)	
			)	Art Unit:
Cnfrm. No.	:	To Be Assigned	)	To Be Assigned
			)	
Filed	:	Herewith	)	
			)	
For	:	YOHIMBINE DIMERS EXHIBITING BINDING)	)	
		SELECTIVITIES FOR $\alpha_2$ ADRENERGIC	)	
		RECEPTORS	)	

---

INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR §§ 1.97-1.98

**Mail Stop: Patent Application**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450


Dear Sir:

Pursuant to 37 CFR §§ 1.97-1.98, applicants hereby bring to the attention of the United States Patent and Trademark Office, the enclosed references listed on the attached PTO-1449 form.

Pursuant to 37 CFR § 1.98(d), the references identified on the attached PTO-1449 form are not provided, because these references either were previously cited by or submitted to the PTO in parent U.S. Patent Application Serial No. 10/106,521, filed March 25, 2002, of which this application claims priority under 35 USC § 120.

Respectfully submitted,

Date: October 6, 2003

  
Edwin V. Merkel  
Registration No. 40,087

NIXON PEABODY LLP  
Clinton Square, P.O. Box 31051  
Rochester, New York 14603-1051  
Telephone: (585) 263-1128  
Facsimile: (585) 263-1600

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (use several sheets if necessary)  (PTO-1449 )	ATTY. DOCKET NO. 20609/203 (PD 00034)		SERIAL NO. Division of 10/106,521
	APPLICANT Miller et al.		
	FILING DATE Herewith		GROUP ART UNIT To be Assigned

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPRO- PRIATE
	1	3,940,387	02/24/1976	Saint-Ruf et al.			

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANS- LATION IF APPRO- PRIATE

## OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)

		2	Portoghese et al., "Stereostructure-Activity Relationship of Opioid Agonist and Antagonist Bivalent Ligands. Evidence for Bridging Between Vicinal Opioid Receptors," <u>J. Med. Chem.</u> 28:1140-41 (1985)
		3	Erez et al., "Narcotic Antagonist Potency of Bivalent Ligands Which Contain $\beta$ -Naltrexamine. Evidence for Bridging Between Proximal Recognition Sites," <u>J. Med. Chem.</u> 25:847-849 (1982)
		4	Philip S. Portoghese, "The Role of Concepts in Structure-Activity Relationship Studies of Opioid Ligands," <u>Journal of Medicinal Chemistry</u> 35(11):1927-1937 (1992)
		5	Philip S. Portoghese, "Bivalent Ligands and the Message-Address Concept in the Design of Selective Opioid Receptor Antagonists," <u>TIPS Review</u> 10:230-235 (1989)
		6	Shimohigashi et al., "Dimeric Tetrapeptide Enkephalins Display Extraordinary Selectivity for the $\delta$ Opiate Receptor," <u>Nature</u> 297:333-335 (1982)
		7	LeBoulluec et al., "Bivalent Indoles Exhibiting Serotonergic Binding Affinity," <u>Bioorganic &amp; Medicinal Chemistry Letters</u> , 5:123-126 (1995)
		8	Cwirla et al., "Peptide Agonist of the Thrombopoietin Receptor as Potent as the Natural Cytokine," <u>Science</u> 276:1696-1699 (1997)
EXAMINER			DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (use several sheets if necessary)  (PTO-1449 )	ATTY. DOCKET NO. 20609/203 (PD 00034)	SERIAL NO. Division of 10/106,521
	APPLICANT Miller et al.	
	FILING DATE Herewith	GROUP ART UNIT To be Assigned

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPRO- PRIATE

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRAN- SLATION IF APPRO- PRIATE

## OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)

		9	Uhlén et al., "Membrane Organization and Mobility of $\alpha_2$ Adrenergic Receptors in MDCK Cells," <u>Pharmacology Communications</u> 6(1-3):155-167 (1995)
		10	Maggio et al., "Coexpression Studies with Mutant Muscarinic/Adrenergic Receptors Provide Evidence for Intermolecular "Cross-Talk" Between G-Protein-Linked Receptors," <u>Proc. Natl. Acad. Sci. USA</u> 90:3103-3107 (1993)
		11	Maggio et al., "Functional Role of the Third Cytoplasmic Loop in Muscarinic Receptor Dimerization," <u>The Journal of Biological Chemistry</u> 271(49):31055-31060 (1996)
		12	Zheng, et al., "Yohimbine Dimers Exhibiting Binding Selectivities for Human $\alpha_{2a}$ - versus $\alpha_{2b}$ -Adrenergic Receptors," <u>Biorg. Med. Chem. Lett.</u> 10:627-630 (2000)
EXAMINER			DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			